Figure 1. The cytotoxic activity against HubCCA1 cell line after the priming with sunitinib-pretreated DCs.

The CIK cells (A) at 1.0×10⁵ cells/well from each condition were incubated with the attached HubCCA1 cells (5,000 cells/well) for 4 h before the PI assay. The CIK cell preparations comprised untreated condition, direct sunitinib treatment, macrophage co-culture, sunitinib-treated macrophage co-culture, iDC co-culture, and sunitinib-treated iDC co-culture, mDC co-culture, and sunitinib-treated mDC co-culture. The isolated CD3⁺CD56⁺ cells (B) were studied in similar fashion. These included untreated CD3⁺CD56⁺ cells, direct sunitinib treatment, mDC co-culture, and sunitinib-treated mDC co-culture. * and ** designate data with significant different from those of the untreated CIK cells at the same effector to target (E:T) ratio with p<0.05 and <0.01 respectively.